You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Advanced ALK-positive lung cancer with lorlatinib versus crizotinib in Asian patients with brain metastases
  1. Hung Shih-Chang
  1. Nantou Hospital, Nantou, Taiwan
  1. Correspondence to Dr Hung Shih-Chang, Nantou Hospital, Nantou, Taiwan; shihchan{at}gmail.com

http://dx.doi.org/10.1136/ejhpharm-2021-003018

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I read with interest the work by Shaw et al entitled ‘First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer’. The findings of this study are very inspiring for lung cancer treatment in Asian patients, especially those with brain metastases.1 I note that lorlatinib was found to be a very important treatment option in progression-free survival and overall survival rate. The hazard ratios (HRs) favoured lorlatinib over crizotinib across all subgroups of patients. In online supplemental figure S1, the HR was 0.32 (95% CI 0.20 to 0.49) for lorlatinib compared with crizotinib in the group with non-brain metastases, whereas it was …

    View Full Text

    Footnotes

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.